Sheng,
Qing
a Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02115, United States
b Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, United States
c Harvard Medical School, Boston, MA 02115, United States
d Department of Pathology, Brigham and Women's Hospital, Boston, MA 02115, United States
e Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, United States
f Novartis Oncology, Cambridge, MA 02139, United States
g Department I of Internal Medicine, Center of Integrated Oncology, University of Köln, D-50937 Köln, Germany
h Chemical Genomics Center, the Max Planck Society, D-44227 Dortmund, Germany
i Broad Institute, Harvard University, the Massachusetts Institute of Technology, Cambridge, MA 02142, United States
j Merrimack Pharmaceuticals, Cambridge, MA 02139, United States
k Department of Pediatric Oncology, Dana-Farber Cancer Institute, Children's Hospital, Boston, MA 02115, United States;
Liu,
Xinggang
a Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02115, United States
b Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, United States
c Harvard Medical School, Boston, MA 02115, United States
d Department of Pathology, Brigham and Women's Hospital, Boston, MA 02115, United States
e Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, United States
f Novartis Oncology, Cambridge, MA 02139, United States
g Department I of Internal Medicine, Center of Integrated Oncology, University of Köln, D-50937 Köln, Germany
h Chemical Genomics Center, the Max Planck Society, D-44227 Dortmund, Germany
i Broad Institute, Harvard University, the Massachusetts Institute of Technology, Cambridge, MA 02142, United States
j Merrimack Pharmaceuticals, Cambridge, MA 02139, United States
k Department of Pediatric Oncology, Dana-Farber Cancer Institute, Children's Hospital, Boston, MA 02115, United States;
Fleming,
Eleanor
a Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02115, United States
b Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, United States
c Harvard Medical School, Boston, MA 02115, United States
d Department of Pathology, Brigham and Women's Hospital, Boston, MA 02115, United States
e Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, United States
f Novartis Oncology, Cambridge, MA 02139, United States
g Department I of Internal Medicine, Center of Integrated Oncology, University of Köln, D-50937 Köln, Germany
h Chemical Genomics Center, the Max Planck Society, D-44227 Dortmund, Germany
i Broad Institute, Harvard University, the Massachusetts Institute of Technology, Cambridge, MA 02142, United States
j Merrimack Pharmaceuticals, Cambridge, MA 02139, United States
k Department of Pediatric Oncology, Dana-Farber Cancer Institute, Children's Hospital, Boston, MA 02115, United States;
Yuan,
Karen
a Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02115, United States
b Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, United States
c Harvard Medical School, Boston, MA 02115, United States
d Department of Pathology, Brigham and Women's Hospital, Boston, MA 02115, United States
e Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, United States
f Novartis Oncology, Cambridge, MA 02139, United States
g Department I of Internal Medicine, Center of Integrated Oncology, University of Köln, D-50937 Köln, Germany
h Chemical Genomics Center, the Max Planck Society, D-44227 Dortmund, Germany
i Broad Institute, Harvard University, the Massachusetts Institute of Technology, Cambridge, MA 02142, United States
j Merrimack Pharmaceuticals, Cambridge, MA 02139, United States
k Department of Pediatric Oncology, Dana-Farber Cancer Institute, Children's Hospital, Boston, MA 02115, United States;
Chen,
Jinyun
a Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02115, United States
b Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, United States
c Harvard Medical School, Boston, MA 02115, United States
d Department of Pathology, Brigham and Women's Hospital, Boston, MA 02115, United States
e Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, United States
f Novartis Oncology, Cambridge, MA 02139, United States
g Department I of Internal Medicine, Center of Integrated Oncology, University of Köln, D-50937 Köln, Germany
h Chemical Genomics Center, the Max Planck Society, D-44227 Dortmund, Germany
i Broad Institute, Harvard University, the Massachusetts Institute of Technology, Cambridge, MA 02142, United States
j Merrimack Pharmaceuticals, Cambridge, MA 02139, United States
k Department of Pediatric Oncology, Dana-Farber Cancer Institute, Children's Hospital, Boston, MA 02115, United States;
Moustafa,
Zeinab
a Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02115, United States
b Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, United States
c Harvard Medical School, Boston, MA 02115, United States
d Department of Pathology, Brigham and Women's Hospital, Boston, MA 02115, United States
e Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, United States
f Novartis Oncology, Cambridge, MA 02139, United States
g Department I of Internal Medicine, Center of Integrated Oncology, University of Köln, D-50937 Köln, Germany
h Chemical Genomics Center, the Max Planck Society, D-44227 Dortmund, Germany
i Broad Institute, Harvard University, the Massachusetts Institute of Technology, Cambridge, MA 02142, United States
j Merrimack Pharmaceuticals, Cambridge, MA 02139, United States
k Department of Pediatric Oncology, Dana-Farber Cancer Institute, Children's Hospital, Boston, MA 02115, United States;
/persons/resource/persons147315
Thomas,
Roman K.
Funktionelle Krebsgenomforschung, Junior Research Groups, Max-Planck-Institut für neurologische Forschung, Managing Director: D. Yves von Cramon, Max Planck Institute for Metabolism Research, Managing Director: Jens Brüning, Max Planck Society;
Greulich,
Heidi
a Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02115, United States
b Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, United States
c Harvard Medical School, Boston, MA 02115, United States
d Department of Pathology, Brigham and Women's Hospital, Boston, MA 02115, United States
e Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, United States
f Novartis Oncology, Cambridge, MA 02139, United States
g Department I of Internal Medicine, Center of Integrated Oncology, University of Köln, D-50937 Köln, Germany
h Chemical Genomics Center, the Max Planck Society, D-44227 Dortmund, Germany
i Broad Institute, Harvard University, the Massachusetts Institute of Technology, Cambridge, MA 02142, United States
j Merrimack Pharmaceuticals, Cambridge, MA 02139, United States
k Department of Pediatric Oncology, Dana-Farber Cancer Institute, Children's Hospital, Boston, MA 02115, United States;
Schinzel,
Anna C.
a Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02115, United States
b Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, United States
c Harvard Medical School, Boston, MA 02115, United States
d Department of Pathology, Brigham and Women's Hospital, Boston, MA 02115, United States
e Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, United States
f Novartis Oncology, Cambridge, MA 02139, United States
g Department I of Internal Medicine, Center of Integrated Oncology, University of Köln, D-50937 Köln, Germany
h Chemical Genomics Center, the Max Planck Society, D-44227 Dortmund, Germany
i Broad Institute, Harvard University, the Massachusetts Institute of Technology, Cambridge, MA 02142, United States
j Merrimack Pharmaceuticals, Cambridge, MA 02139, United States
k Department of Pediatric Oncology, Dana-Farber Cancer Institute, Children's Hospital, Boston, MA 02115, United States;
Zaghlul,
Sara
a Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02115, United States
b Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, United States
c Harvard Medical School, Boston, MA 02115, United States
d Department of Pathology, Brigham and Women's Hospital, Boston, MA 02115, United States
e Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, United States
f Novartis Oncology, Cambridge, MA 02139, United States
g Department I of Internal Medicine, Center of Integrated Oncology, University of Köln, D-50937 Köln, Germany
h Chemical Genomics Center, the Max Planck Society, D-44227 Dortmund, Germany
i Broad Institute, Harvard University, the Massachusetts Institute of Technology, Cambridge, MA 02142, United States
j Merrimack Pharmaceuticals, Cambridge, MA 02139, United States
k Department of Pediatric Oncology, Dana-Farber Cancer Institute, Children's Hospital, Boston, MA 02115, United States;
Batt,
David
a Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02115, United States
b Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, United States
c Harvard Medical School, Boston, MA 02115, United States
d Department of Pathology, Brigham and Women's Hospital, Boston, MA 02115, United States
e Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, United States
f Novartis Oncology, Cambridge, MA 02139, United States
g Department I of Internal Medicine, Center of Integrated Oncology, University of Köln, D-50937 Köln, Germany
h Chemical Genomics Center, the Max Planck Society, D-44227 Dortmund, Germany
i Broad Institute, Harvard University, the Massachusetts Institute of Technology, Cambridge, MA 02142, United States
j Merrimack Pharmaceuticals, Cambridge, MA 02139, United States
k Department of Pediatric Oncology, Dana-Farber Cancer Institute, Children's Hospital, Boston, MA 02115, United States;
Ettenberg,
Seth
a Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02115, United States
b Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, United States
c Harvard Medical School, Boston, MA 02115, United States
d Department of Pathology, Brigham and Women's Hospital, Boston, MA 02115, United States
e Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, United States
f Novartis Oncology, Cambridge, MA 02139, United States
g Department I of Internal Medicine, Center of Integrated Oncology, University of Köln, D-50937 Köln, Germany
h Chemical Genomics Center, the Max Planck Society, D-44227 Dortmund, Germany
i Broad Institute, Harvard University, the Massachusetts Institute of Technology, Cambridge, MA 02142, United States
j Merrimack Pharmaceuticals, Cambridge, MA 02139, United States
k Department of Pediatric Oncology, Dana-Farber Cancer Institute, Children's Hospital, Boston, MA 02115, United States;
Meyerson,
Matthew
a Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02115, United States
b Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, United States
c Harvard Medical School, Boston, MA 02115, United States
d Department of Pathology, Brigham and Women's Hospital, Boston, MA 02115, United States
e Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, United States
f Novartis Oncology, Cambridge, MA 02139, United States
g Department I of Internal Medicine, Center of Integrated Oncology, University of Köln, D-50937 Köln, Germany
h Chemical Genomics Center, the Max Planck Society, D-44227 Dortmund, Germany
i Broad Institute, Harvard University, the Massachusetts Institute of Technology, Cambridge, MA 02142, United States
j Merrimack Pharmaceuticals, Cambridge, MA 02139, United States
k Department of Pediatric Oncology, Dana-Farber Cancer Institute, Children's Hospital, Boston, MA 02115, United States;
Schoeberl,
Birgit
a Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02115, United States
b Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, United States
c Harvard Medical School, Boston, MA 02115, United States
d Department of Pathology, Brigham and Women's Hospital, Boston, MA 02115, United States
e Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, United States
f Novartis Oncology, Cambridge, MA 02139, United States
g Department I of Internal Medicine, Center of Integrated Oncology, University of Köln, D-50937 Köln, Germany
h Chemical Genomics Center, the Max Planck Society, D-44227 Dortmund, Germany
i Broad Institute, Harvard University, the Massachusetts Institute of Technology, Cambridge, MA 02142, United States
j Merrimack Pharmaceuticals, Cambridge, MA 02139, United States
k Department of Pediatric Oncology, Dana-Farber Cancer Institute, Children's Hospital, Boston, MA 02115, United States;
Kung,
Andrew L.
a Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02115, United States
b Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, United States
c Harvard Medical School, Boston, MA 02115, United States
d Department of Pathology, Brigham and Women's Hospital, Boston, MA 02115, United States
e Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, United States
f Novartis Oncology, Cambridge, MA 02139, United States
g Department I of Internal Medicine, Center of Integrated Oncology, University of Köln, D-50937 Köln, Germany
h Chemical Genomics Center, the Max Planck Society, D-44227 Dortmund, Germany
i Broad Institute, Harvard University, the Massachusetts Institute of Technology, Cambridge, MA 02142, United States
j Merrimack Pharmaceuticals, Cambridge, MA 02139, United States
k Department of Pediatric Oncology, Dana-Farber Cancer Institute, Children's Hospital, Boston, MA 02115, United States;
Hahn,
William C.
a Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02115, United States
b Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, United States
c Harvard Medical School, Boston, MA 02115, United States
d Department of Pathology, Brigham and Women's Hospital, Boston, MA 02115, United States
e Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, United States
f Novartis Oncology, Cambridge, MA 02139, United States
g Department I of Internal Medicine, Center of Integrated Oncology, University of Köln, D-50937 Köln, Germany
h Chemical Genomics Center, the Max Planck Society, D-44227 Dortmund, Germany
i Broad Institute, Harvard University, the Massachusetts Institute of Technology, Cambridge, MA 02142, United States
j Merrimack Pharmaceuticals, Cambridge, MA 02139, United States
k Department of Pediatric Oncology, Dana-Farber Cancer Institute, Children's Hospital, Boston, MA 02115, United States;
Drapkin,
Ronny
a Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02115, United States
b Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, United States
c Harvard Medical School, Boston, MA 02115, United States
d Department of Pathology, Brigham and Women's Hospital, Boston, MA 02115, United States
e Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, United States
f Novartis Oncology, Cambridge, MA 02139, United States
g Department I of Internal Medicine, Center of Integrated Oncology, University of Köln, D-50937 Köln, Germany
h Chemical Genomics Center, the Max Planck Society, D-44227 Dortmund, Germany
i Broad Institute, Harvard University, the Massachusetts Institute of Technology, Cambridge, MA 02142, United States
j Merrimack Pharmaceuticals, Cambridge, MA 02139, United States
k Department of Pediatric Oncology, Dana-Farber Cancer Institute, Children's Hospital, Boston, MA 02115, United States;
Livingston,
David M.
a Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02115, United States
b Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, United States
c Harvard Medical School, Boston, MA 02115, United States
d Department of Pathology, Brigham and Women's Hospital, Boston, MA 02115, United States
e Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, United States
f Novartis Oncology, Cambridge, MA 02139, United States
g Department I of Internal Medicine, Center of Integrated Oncology, University of Köln, D-50937 Köln, Germany
h Chemical Genomics Center, the Max Planck Society, D-44227 Dortmund, Germany
i Broad Institute, Harvard University, the Massachusetts Institute of Technology, Cambridge, MA 02142, United States
j Merrimack Pharmaceuticals, Cambridge, MA 02139, United States
k Department of Pediatric Oncology, Dana-Farber Cancer Institute, Children's Hospital, Boston, MA 02115, United States;
Liu,
Joyce
a Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02115, United States
b Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, United States
c Harvard Medical School, Boston, MA 02115, United States
d Department of Pathology, Brigham and Women's Hospital, Boston, MA 02115, United States
e Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, United States
f Novartis Oncology, Cambridge, MA 02139, United States
g Department I of Internal Medicine, Center of Integrated Oncology, University of Köln, D-50937 Köln, Germany
h Chemical Genomics Center, the Max Planck Society, D-44227 Dortmund, Germany
i Broad Institute, Harvard University, the Massachusetts Institute of Technology, Cambridge, MA 02142, United States
j Merrimack Pharmaceuticals, Cambridge, MA 02139, United States
k Department of Pediatric Oncology, Dana-Farber Cancer Institute, Children's Hospital, Boston, MA 02115, United States;